Abstract 391P
Background
Lip cancer represents 1-2% of malgnancies and accounts for 23.6-30% of all oral cancers. It is more common in the lower lip, However, it may appear in the upper lip also. Squamous cell carcinoma is the most common subtype. There is limited data to evaluate racial disparites into different age groups. So this study aims to evaluate the long-term survival outcome for lip cancer in the young and adults compared to the elderly and consider racial disparities.
Methods
Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) Program. We obtained data of patients diagnosed with lip cancer from 2000-2020. The age groups have been classified into two groups according to the National Institute of Age and divided into young and adults if less than 65 years while the old age starting from 65 years.
Results
The majority were Caucasians (99279 patients) and 114 only were African Americans. The 5-year relative survival for lip cancer in the young and adults age group was 92.6%, while in the old age group was 88.9%; P>0.0001. The 5-year relative survival of African Americans in the young and adult age was 85.9% while for Caucasiasns it was 92.5%, and in African Americans elderly the 5-year relative survival was 60.4% while in Caucasian was 88.9%; P >0.0001. The 5-year relative survival for lip cancer in localized SEER stage at the young and adults age group was 95.4%, while in the old age group 92.4% And the 5-year relative survival for lip cancer in distant stage of the disease at young and adults age group was 52.1%, while in the old age group it was 27.7%. Patients treated with combined chemoradiotherapy had a 5-year relative survival of 52.3%, while those who had no systemic therapy had a 5-year relative survival of 93.2%.
Conclusions
In this study, the results highlight significant differences in the long-term survival outcomes; Caucasians are more susceptible to devolop lip cancer than African Americans. However, African Americans have lower survival rates than Caucasians. Due to the early discovery of lip cancer, the standard treatment modality is surgical resection, which explains the significantly decreased survival related to adjuvant chemo(radio)therapy. So we recommend to avoid the systemic therapy for less unfavrouble side effect.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract